Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2017, Article ID 4803156, 9 pages
https://doi.org/10.1155/2017/4803156
Research Article

The Metabolic Syndrome, Inflammation, and Colorectal Cancer Risk: An Evaluation of Large Panels of Plasma Protein Markers Using Repeated, Prediagnostic Samples

Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden

Correspondence should be addressed to Bethany Van Guelpen; es.umu@nepleugnav.ynahteb

Received 15 December 2016; Accepted 27 February 2017; Published 22 March 2017

Academic Editor: Shengzhong Duan

Copyright © 2017 Sophia Harlid et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. Esposito, P. Chiodini, A. Colao, A. Lenzi, and D. Giugliano, “Metabolic syndrome and risk of cancer: a systematic review and meta-analysis,” Diabetes Care, vol. 35, no. 11, pp. 2402–2411, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. E. S. Ford, “Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence,” Diabetes Care, vol. 28, no. 7, pp. 1769–1778, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Galassi, K. Reynolds, and J. He, “Metabolic syndrome and risk of cardiovascular disease: a meta-analysis,” The American Journal of Medicine, vol. 119, no. 10, pp. 812–819, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Harding, M. Sooriyakumaran, K. J. Anstey et al., “The metabolic syndrome and cancer: is the metabolic syndrome useful for predicting cancer risk above and beyond its individual components?” Diabetes & Metabolism, vol. 41, no. 6, pp. 463–469, 2015. View at Publisher · View at Google Scholar · View at Scopus
  5. S. M. Grundy, J. I. Cleeman, S. R. Daniels et al., “Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement,” Circulation, vol. 112, no. 17, pp. 2735–2752, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Kaur, “A comprehensive review on metabolic syndrome,” Cardiology Research and Practice, vol. 2014, Article ID 943162, p. 21, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. A. J. McCullough, “Epidemiology of the metabolic syndrome in the USA,” Journal of Digestive Diseases, vol. 12, no. 5, pp. 333–340, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. K. Srikanthan, A. Feyh, H. Visweshwar, J. I. Shapiro, and K. Sodhi, “Systematic review of metabolic syndrome biomarkers: a panel for early detection, management, and risk stratification in the West Virginian population,” International Journal of Medical Sciences, vol. 13, no. 1, pp. 25–38, 2016. View at Publisher · View at Google Scholar · View at Scopus
  9. F. K. Welty, A. Alfaddagh, and T. K. Elajami, “Targeting inflammation in metabolic syndrome,” Translational Research, vol. 167, no. 1, pp. 257–280, 2016. View at Publisher · View at Google Scholar · View at Scopus
  10. K. Aleksandrova, H. Boeing, M. Jenab et al., “Metabolic syndrome and risks of colon and rectal cancer: the European prospective investigation into cancer and nutrition study,” Cancer Prevention Research (Philadelphia, Pa.), vol. 4, no. 11, pp. 1873–1883, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. K. Esposito, P. Chiodini, A. Capuano et al., “Colorectal cancer association with metabolic syndrome and its components: a systematic review with meta-analysis,” Endocrine, vol. 44, no. 3, pp. 634–647, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Norberg, S. Wall, K. Boman, and L. Weinehall, “The Vasterbotten Intervention Programme: background, design and implications,” Global Health Action, vol. 3, 2010. View at Publisher · View at Google Scholar
  13. S. Braun, K. Bitton-Worms, and D. LeRoith, “The link between the metabolic syndrome and cancer,” International Journal of Biological Sciences, vol. 7, no. 7, pp. 1003–1015, 2011. View at Google Scholar
  14. F. M. Mendonça, F. R. de Sousa, A. L. Barbosa et al., “Metabolic syndrome and risk of cancer: which link?” Metabolism, Clinical and Experimental, vol. 64, no. 2, pp. 182–189, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Kralisch, A. Tönjes, K. Krause et al., “Fibroblast growth factor-21 serum concentrations are associated with metabolic and hepatic markers in humans,” Journal of Endocrinology, vol. 216, no. 2, pp. 135–143, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. X. Zhang, D. C. Yeung, M. Karpisek et al., “Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans,” Diabetes, vol. 57, no. 5, pp. 1246–1253, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Beenken and M. Mohammadi, “The FGF family: biology, pathophysiology and therapy,” Nature Reviews. Drug Discovery, vol. 8, no. 3, pp. 235–253, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. S. A. Kliewer and D. J. Mangelsdorf, “Fibroblast growth factor 21: from pharmacology to physiology,” The American Journal of Clinical Nutrition, vol. 91, no. 1, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Kralisch and M. Fasshauer, “Fibroblast growth factor 21: effects on carbohydrate and lipid metabolism in health and disease,” Current Opinion in Clinical Nutrition and Metabolic Care, vol. 14, no. 4, pp. 354–359, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. K. R. Markan, M. C. Naber, M. K. Ameka et al., “Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding,” Diabetes, vol. 63, no. 12, pp. 4057–4063, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. X. Cheng, B. Zhu, F. Jiang, and H. Fan, “Serum FGF-21 levels in type 2 diabetic patients,” Endocrine Research, vol. 36, no. 4, pp. 142–148, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. M. E. Knott, J. N. Minatta, L. Roulet et al., “Circulating fibroblast growth factor 21 (Fgf21) as diagnostic and prognostic biomarker in renal cancer,” Journal of Molecular Biomarkers & Diagnosis, vol. 1, Supplement 2, 2016. View at Publisher · View at Google Scholar
  23. J. M. G. Taylor, D. P. Ankerst, and R. R. Andridge, “Validation of biomarker-based risk prediction models,” Clinical Cancer Research, vol. 14, no. 19, pp. 5977–5983, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Hiratsuka, H. Adachi, Y. Fujiura et al., “Strong association between serum hepatocyte growth factor and metabolic syndrome,” The Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 5, pp. 2927–2931, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. C. Ueyama, H. Horibe, Y. Yamase et al., “Association of FURIN and ZPR1 polymorphisms with metabolic syndrome,” Biomedical Reports, vol. 3, no. 5, pp. 641–647, 2015. View at Publisher · View at Google Scholar
  26. Y. Vistoropsky, S. Trofimov, I. Malkin, E. Kobyliansky, and G. Livshits, “Genetic and environmental determinants of hepatocyte growth factor levels and their association with obesity and blood pressure,” Annals of Human Biology, vol. 35, no. 1, pp. 93–103, 2008. View at Google Scholar
  27. Y. Ren, B. Cao, S. Law et al., “Hepatocyte growth factor promotes cancer cell migration and angiogenic factors expression: a prognostic marker of human esophageal squamous cell carcinomas,” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, vol. 11, no. 17, pp. 6190–6197, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. G. Thomas, “Furin at the cutting edge: from protein traffic to embryogenesis and disease,” Nature Reviews. Molecular Cell Biology, vol. 3, no. 10, pp. 753–766, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. J. M. Coppola, M. S. Bhojani, B. D. Ross, and A. Rehemtulla, “A small-molecule furin inhibitor inhibits cancer cell motility and invasiveness,” Neoplasia (New York, N.Y.), vol. 10, no. 4, pp. 363–370, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. Y.-H. H. Huang, K.-H. H. Lin, C.-H. H. Liao, M. W. Lai, Y. H. Tseng, and C. T. Yeh, “Furin overexpression suppresses tumor growth and predicts a better postoperative disease-free survival in hepatocellular carcinoma,” PloS One, vol. 7, no. 7, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. N. Y. Ji, Y.-H. H. Kim, Y. J. Jang et al., “Identification of endothelial cell-specific molecule-1 as a potential serum marker for colorectal cancer,” Cancer Science, vol. 101, no. 10, pp. 2248–2253, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. Y. H. Kang, N. Y. Ji, S. R. Han et al., “ESM-1 regulates cell growth and metastatic process through activation of NF-κB in colorectal cancer,” Cellular Signalling, vol. 24, no. 10, pp. 1940–1949, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Pigoni, J. Wanngren, P.-H. H. Kuhn et al., “Seizure protein 6 and its homolog seizure 6-like protein are physiological substrates of BACE1 in neurons,” Molecular Neurodegeneration, vol. 11, no. 1, p. 67, 2016. View at Publisher · View at Google Scholar
  34. I. P. Gorlov, P. Meyer, T. Liloglou et al., “Seizure 6-like (SEZ6L) gene and risk for lung cancer,” Cancer Research, vol. 67, no. 17, pp. 8406–8411, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Devaraj, U. Singh, and I. Jialal, “Human C-reactive protein and the metabolic syndrome,” Current Opinion in Lipidology, vol. 20, no. 3, pp. 182–189, 2009. View at Publisher · View at Google Scholar · View at Scopus